99% pure AICAR powder

Aminoimidazole-4-carboxamide ribonucleotide (AICAR) is an intermediate in the generation of inosine monophosphate. AICAR is an analog of adenosine monophosphate (AMP) that is capable of stimulating AMP-dependent protein kinase (AMPK) activity. AICAR has been used clinically to treat and protect against cardiac ischemic injury. The drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery. Currently, the drug has also been shown as a potential treatment for diabetes by increasing the metabolic activity of tissues by changing the physical composition of muscle.

 

Medical use

A brief period of coronary arterial occlusion followed by reperfusion prior to prolonged ischemia is known as preconditioning. It has been shown that this is protective. Preconditioning preceded myocardial infarction, may delay cell death and allow for greater salvage of myocardium through reperfusion therapy.

AICAR has been shown to precondition the heart shortly before or during ischemia. AICAR triggers a preconditioned anti-inflammatory state by increasing NO production from endothelial nitric oxide synthase. When AICAR is given 24 hours prior to reperfusion, it prevents post ischemic leukocyte-endothelial cell adhesive interactions with increased NO production. AICAR-dependent preconditioning is also mediated by an ATP-sensitive potassium channel and hemeoxygenase-dependent mechanism. It increases AMPK-dependent recruitment of ATP-sensitive K channels to the sarcolemma causing the action potentialduration to shorten, and preventing calcium overload during reperfusion. The decrease in calcium overload prevents inflammation activation by ROS. AICAR also increases AMPK-dependent glucose uptake through translocation of GLUT-4 which is beneficial for the heart during post-ischemic reperfusion.The increase in glucose during AICAR preconditioning lengthens the period for preconditioning up to 2 hours in rabbits and 40 minutes in humans undergoing coronary ligation. As a result, AICAR reduces the frequency and size of myocardial infarcts up to 25% in humans allowing improved blood flow to the heart. As well, the treatment has been shown to decrease the risk of an early death and improve recovery after surgery from an ischemic injury.

 

Product Information

Chemical formula C9H15N4O8P
Molar mass 338.21 g·mol−1
M. Wt 258.23
Formula C9H14N4O5
Storage Store at -20°C
Purity ≥99% (HPLC)
CAS Number 2627-69-2
PubChem ID 17513
Color  White powder
Melting Point 214-215 °C

 

High Qulity Certificate of Analysis

Product Name AICAR
Batch No 20180808
Quantity 500G Produce Date 2018.07.30
Ref Standard   Exp Date 2019.08.08
Items And Results
Item Quality level Determination
Assay by HPLC: ≥99.0% 99.20%
Appearance White powder Conforms
HNMR Conforms to structure Conforms
LCMS Conforms to MW Conforms
Conclusion Passed
Packing description Sealed export grade drum & double of sealed plastic bag
Storage Store in cool & dry place not freeze, keep away from strong light and heat
Shelf life 1 years when properly stored